Systemic Sclerosis and Inflammatory Myopathies Flashcards

(41 cards)

1
Q

What are the two main subsets of scleroderma?

A

limited cutaneous and diffuse cutaneous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What genes are involved in scleroderma?

A

HLA-DRB1, STAT4, interferon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What environmental factors are associated with scleroderma?

A

silica, organic solvents, vinyl chloride

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the three pathologic pillars of systemic sclerosis?

A

inflammation (synovitis, myositis), vasculopathy (raynaud’s, abnormal capillaries, ischaemic changes) and interstitial fibrosis (in skin = scleroderma, but also happens in other organs e.g. lung, gut, renal)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the difference between diffuse cutaneous and limited cutaenous?

A

diffuse has a more rapid onset, has earlier internal organ involvement, more constitutional symptoms
in limited cutaneous skin changes are limited to arms and face

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which antibodies are associated with diffuse cutaneous scleroderma?

A

Scl-70 antibodies, anti-RNA polymerase I, III, ANA with nucleolar pattern

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is CREST syndrome?

A

limited cutaneous scleroderma: Calcinosis, Raynaud’s, oEsophageal dysmotility, Skin changes, Telangiectasia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What antibodies are associated with limited cutaneous scleroderma?

A

anti-centromere antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Is pulmonary arterial hypertension more common in diffuse or limited?

A

equal 10% in both

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Is ILD more common in diffuse or limited?

A

diffuse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Is scleroderma renal crisis more common in diffuse or limited?

A

diffuse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What organ involvement is associated with anti Scl-70 antibody?

A

intestitial lung disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What organ involvement is associated with centromere antibodies?

A

protection from ILD and renal disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What organ involvement is associated with anti RNA polymerase III antibodies?

A

renal, skin, malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the leading cause of death in scleroderma?

A

cardiopulmonary manifestations - pulmonary fibrosis, pulmonary hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the treatment for scleroderma?

A

no overall disease modifying therapy - organ specific treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How do you diagnose interstitial lung disease?

A

high resolution CT shows non specific interstitial pneumonitis

18
Q

Which patients with ILD should be treated?

A

patients with early diffuse scleroderma with positive anti-Scl70 or elevated CRP, or based on the grade of disease on HRCT, FVC% or DLCO % less than lower limit of normal or clinically meaningful decline, desaturating on 6MWT, symptoms from ILD

19
Q

How often should patients get spirometry?

A

for every 3-4 months for the first 5 years and then yearly

20
Q

What conservative measures can be used to treat ILD?

A

treat GORD, quit smoking, vaccinations, supplemental O2

21
Q

What is first line therapy for ILD?

A

mycophenolate 3g/day

22
Q

What are other reasons patients with scleroderma may have declining DLCO other than ILD?

A

neuromusclar dysfunction (myositis), thoracic restriction (scleroderma), aspiriation (GORD), deconditioning, pulmonary hypertension

23
Q

How do you diagnose pulmonary hypertension?

A

with right heart catheter

24
Q

What screening should be done for scleroderma patients for PAH?

A

TTE and RFTs OR pro-BNP and RFTs

25
What is the therapy for scleroderma associated PAH?
endothelial receptor antagonist or PDE-5 inhibitor or riociguat
26
What are the features of scleroderma renal crisis?
abrupt onset of moderate to severe hypertension, normal urine sediment, progressive renal failure
27
How common is scleroderma renal crisis in diffuse scleroderma?
10-20%
28
What is a trigger for scleroderma renal crisis?
corticosteroids
29
What is the treatment for scleroderma renal crisis?
effective and prompt blood pressure control with an ACE inhibitor
30
What is the treatment for raynaud's phenomenon?
dihydropyridine calcium channel blockers, PDE5 inhibitors, topical nitrates
31
What are the different types of gut involvement in scleroderma?
rigidity of facial muscles/tongue, reduced saliva production, incoordination of swallowing, GORD, bloating, distension, bacterial overgorwth, intussucception, pneumatosis intestinalis, faecal incontinence
32
What are the 4 classes of idiopathic inflammatory myopathies?
polymyositis dermatomyositis inclusion body myositis immune mediated necrotising myopathy
33
What are the clinical features of dermatomyositis and polymyositis?
symmetrical proximal muscle weakness
34
What are the features of a dermatomyositis rash?
gottron's papules (on extensor surface MCP and PIP joints), shawl sign, heliotrope rash (around eyes), periungal erythema
35
What are the laboratory findings for DM and PM?
elevated muscle enzymes (CK, transaminases, LDH, aldolase), antinuclear antibodies
36
What non laboratory investigations are useful in DM and PM?
EMG and MRI
37
What screening should be done for malignancy in patients with inflammatory myopathies?
medical history, physical examination of breast, rectal and pelvic examination, age appropriate screening (mammography, colonoscopy)
38
Which malignancies are most commonly associated with dermatomyositis?
cervix, lung, ovaries, pancreas, bladder, stomach
39
What investigations should be done for non malignant complications of inflammatory polymyopathies?
cardiac (TTE and ECG) pulmonary (HRCT, RFTs) oesophageal (oesophageal motility studies)
40
What is the treatment for inflammatory polymyopathies?
high dose glucocorticoids (taper over a year), steroid sparing agents (azathioprine, methotrexate, IVIG, rituximab, plasma exchange)
41
What are the clinical features of inclusion body myositis?
insidious onset of assymetric, proximal leg weakness for up to 5 years weakness of distal finger flexor muscles muscle atrophy dysphagia